Effectiveness of dual and triple antiretroviral therapy in the treatment of HIV-infected children;Efetividade da terapia anti-retroviral dupla e tríplice em crianças infectadas pelo HIV

Jornal de Pediatria

Volumn 82, Issue 4, 2006, Pages 260-265

  Romanelli, Roberta M C ^a   Pinto, Jorge A ^a   Melo, Laura J ^a   Vasconcelos, Mariana A ^a   Pereira, Rafael De Matos ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FUNDAÇÃO HOSPITALAR DO ESTADO DE MINAS GERAIS   (Brazil)

Author keywords

Acquired immunodeficiency syndrome; Anti HIV drugs; Therapy

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CHILD; CHILD CARE; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIDEMIOLOGIC METHODS; FLOW CYTOMETRY; HUMANS; SELF-SUSTAINED SEQUENCE REPLICATION; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33747343951     PISSN: 00217557     EISSN: None     Source Type: Journal    
DOI: 10.2223/JPED.1505     Document Type: Article

References (29)

1. US Food and Drug Administration. Antiretroviral HIV drug approvals and pediatric labeling information [atualizado out 2005]. http://www.fda.gov/oashi/ aids/status.html.
2. Englund JA, Baker CJ, Raskino C, McKinney RE, Petrie B, Fowler MG, et al.; For the AIDS Clinical Trials Group 152 Study Team. Zidovudine, didanosine or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 1997;336:1704-12.
3. McKinney RE Jr, Johnson GM, Stanley K, Yong FH, Keller A, O'Donnell KJ, et al. A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naïve HIV-1 infection. The Pediatric AIDS Clinical Trials Group 300 Study Team. J Pediatr. 1998;133:500-8.
4. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS. AIDS. 1998;12:F151-60.
5. Essajee SM, Kim M, Gonzales C, Rigaud M, Kaul A, Chandwani S, et al. Immunologic and virologic responses to HAART in severely immunocompromised HIV-1 infected children. AIDS. 1999;13:2523-32.
6. Gibb DM. A randomized trial evaluating three NRTI regimens with and without nelfinavir in HIV-infected children: 48 week follow-up from the Penta 5 trial. AIDS. 2000;14 Suppl 4:58.
7. Nachman SA, Stanley K, Yogev R, Pelton S, Wiznia A, Lee S, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children - a Randomized Controlled Trial. JAMA. 2000;283:492-8.
8. Gibb DM, Newberry A, Klein N, Rossi A, Grosch-Woener I, Babiker A. Immune repopulation after HAART in previously untreated HIV-1 infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee. Lancet. 2000;355:1331-2.
9. Burchett SK, Carey V, Yong F, Sullivan J, Sulzbacher S, Civitello L, et al. Virologic activity of didanosine (ddI), zidovudine (AZT) and nevirapine (NVP) combinations in pediatric subjects with advanced HIV disease (ACTG 245). In: 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago. (Abstract 271.)
10. Luzuriaga K, McManus M, Catalina M, Mayack S, Sharkey M, Stevenon M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1 specific immune responses. J Virol. 2000;74:6984-91.
11. Palumbo PE. Antiretroviral therapy of HIV infection in children. Pediatr Clin N Am. 2000;47:155-69.
12. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-1.
13. Sharland M, Gibb D, Giaquinto C. Current evidence for the use of paediatric antiretroviral therapy - a PENTA analysis. Eur J Pediatr. 2000;159:649-56.
14. Gortmaker SL, Hughes M, Cervia J, Brady M, Johnson GM, Seage GR, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-8.
15. de Martino M, Tovo PA, Balducci M, Galli L, Gabiano C, Rezza G, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-7.
16. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L Jr, Ingerman MJ, et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA.1999;282:1627-32.
17. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med. 1999;340:1614-22.
18. Condra JH. Resisting resistance: maximizing the durability of antiretroviral therapy. Ann Intern Med. 1998;128:951-4.
19. Hirschel B, Francioli P. Progress and problems in the fight against AIDS. N Engl J Med. 1998;338:906-8.
20. Tebas P. When should antiretroviral therapy be initiated? Medscape HIV/AIDS. 2002;8. http://www.medscape.com/Medscape/HIV/journal/2002/v08.n01/ mha0117.02.teba/mha0117.02.teba-01.html. Acesso: 01/02/2001.
21. Eron IE. Initial therapy: when to start, what to start with? In: 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb 4-8; Chicago. http://www.medscape.com/viewarticle/416522. Acesso: 28/12/2001.
22. Gallant JE. Antiretroviral therapy: starting, continuing and fixing. Medscape HIV/AIDS Annual Update 2001. http://hiv.medscape.com/Medscape/HIV/ AnnualUpdate/2001/mha.update06.03.gall/mha04.gall-01.html. Acesso: 22/11/2001.
23. Brasil, Ministério da Saúde, Coordenação Nacional DST/AIDS. Guia de tratamento clínico da infecção pelo HIV em crianças. Consenso sobre terapia anti-retroviral para crianças infectadas pelo HIV. Brasília: Ministério da Saúde; 2004. http://www.aids.gov.br/data/documents/storedDocuments/ %7BB8EF5DAF-23AE-4891-AD36-1903553A3174%7D/%7B88FCFB9A-6418-47C5-9D9F- 70440233DE94%7D/consensocriancas2004.pdf. Acesso: 13/03/2005.
24. US Department of Health and Human Services, HIV/AIDS Treatment Information Service. Guidelines for the use of antiretroviral agents in pediatric HIV infection [atualizado 3 nov 2005]. http://aidsinfo.nih.gov/ ContentFiles/PediatricGuidelines.pdf. Acesso: 20/11/2005.
25. Centers for Disease Control and Prevention. Revised classification system of human immunodeficiency virus infection in children less than 13 years of age. MMWR. 1994;43:1-10.
26. Sharland M, di Zub GC, Ramos JT, Blanche S, Gibb DM, PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy in paediatric HIV infection. Pediatric European Network for Treatment of AIDS. HIV Med. 2002;3:215-26.
27. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes and clinical response to highly active antiretroviral therapy. AIDS. 2001;15:2251-7.
28. Mitsuyasu RT. How long can you go? Predictive value of pretreatment CD4+ cell count and viral load. In: 8th Conference on Retroviruses and Opportunistic Infections; 2001 Feb; Chicago. http://www.medscape.com/viewarticle/416528 Acesso: 28/12/2001.
29. Palumbo PE, Raskino C, Fiscus S, Pahwa S, Fowler MG, Spector SA, et al. Predictive value of quantitative plasma HIV RNA and CD4+ lymphocyte count in HIV-infected children. JAMA. 1998;279:756-61.